Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
The Danish biopharma company on Thursday said the FDA accepted its supplemental biologics application in adult growth hormone deficiency for TransCon hGH, which is marketed as Skytrofa for pediatric ...